mRNA-LNP COVID-19 Vaccine Lipids Induce Complement Activation and Production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to Adverse Reactions
International Journal of Molecular Sciences · 22.03.2024 · 25 (7) · 3595
DOI: 10.3390/ijms25073595 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.03.2024. Verfasst von Tamás Bakos und 13 weiteren Autor:innen. Beteiligte Einrichtung: Nanomedicine Research and Education Center, Department of Translational Medicine, Semmelweis University, 1085 Budapest, Hungary. Hauptthemen laut MEDLINE: Complement Inactivating Agents, COVID-19, Nanoparticles. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nanomedicine Research and Education Center, Department of Translational Medicine, Semmelweis University, Budapest, Hungary, Ministry of Culture and Innovation of Hungary, National Research, Development and Innovation Fund, financed under the KDP-2020 funding scheme, European Union Horizon 2020 project.
Abstract (Originalsprache)
A small fraction of people vaccinated with mRNA–lipid nanoparticle (mRNA-LNP)-based COVID-19 vaccines display acute or subacute inflammatory symptoms whose mechanism has not been clarified to date. To better understand the molecular mechanism of these adverse events (AEs), here, we analyzed in vitro the vaccine-induced induction and interrelations of the following two major inflammatory processes: complement (C) activation and release of proinflammatory cytokines. Incubation of Pfizer-BioNTech’s Comirnaty and Moderna’s Spikevax with 75% human serum led to significant increases in C5a, sC5b-9, and Bb but not C4d, indicating C activation mainly via the alternative pathway. Control PEGylated liposomes (Doxebo) also induced C activation, but, on a weight basis, it was ~5 times less effective than that of Comirnaty. Viral or synthetic naked mRNAs had no C-activating effects. In peripheral blood mononuclear cell (PBMC) cultures supplemented with 20% autologous serum, besides C activation, Comirnaty induced the secretion of proinflammatory cytokines in the following order: IL-1α < IFN-γ < IL-1β < TNF-α < IL-6 < IL-8. Heat-inactivation of C in serum prevented a rise in IL-1α, IL-1β, and TNF-α, suggesting C-dependence of these cytokines’ induction, although the C5 blocker Soliris and C1 inhibitor Berinert, which effectively inhibited C activation in both systems, did not suppress the release of any cytokines. These findings suggest that the inflammatory AEs of mRNA-LNP vaccines are due, at least in part, to stimulation of both arms of the innate immune system, whereupon C activation may be causally involved in the induction of some, but not all, inflammatory cytokines. Thus, the pharmacological attenuation of inflammatory AEs may not be achieved via monotherapy with the tested C inhibitors; efficacy may require combination therapy with different C inhibitors and/or other anti-inflammatory agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nanomedicine Research and Education Center, Department of Translational Medicine, Semmelweis University, 1085 Budapest, Hungary.
- SeroScience LCC., 1089 Budapest, Hungary.
- Department of Cardiology, Heart and Vascular Center, Semmelweis University, 1122 Budapest, Hungary.
- Department of Surgical Research and Techniques, Heart and Vascular Center, Semmelweis University, 1089 Budapest, Hungary.
- Hungarian Center of Reference and Excellence, Department of Internal Medicine and Hematology, Semmelweis University, 1088 Budapest, Hungary.
- Etherna Biopharmaceuticals, 2845 Niel, Belgium.
ORCID-Profile: Réka Facskó, László Dézsi, Gábor Szénási, János Szebeni
Förderung
- Nanomedicine Research and Education Center, Department of Translational Medicine, Semmelweis University, Budapest, Hungary
- Ministry of Culture and Innovation of Hungary, National Research, Development and Innovation Fund, financed under the KDP-2020 funding scheme
- European Union Horizon 2020 project
- National Research, Development, and Innovation Office (NKFIH) of Hungary
- Ministry of Culture and Innovation of Hungary, National Research, Development, and Innovation Fund
- National Research, Development, and Innovation Fund
- CSL Behring, Takeda, and Pharming
Zitieren
APA
Bakos, T., Mészáros, T., Kozma, G. T., Berényi, P., Facskó, R., Farkas, H., Dézsi, L., Heirman, C., de Koker, S., Schiffelers, R., Glatter, K. A., Radovits, T., Szénási, G., & Szebeni, J. (2024). mRNA-LNP COVID-19 Vaccine Lipids Induce Complement Activation and Production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to Adverse Reactions. International Journal of Molecular Sciences, 25(7), 3595. https://doi.org/10.3390/ijms25073595
Vancouver
Bakos T, Mészáros T, Kozma GT, Berényi P, Facskó R, Farkas H, et al. mRNA-LNP COVID-19 Vaccine Lipids Induce Complement Activation and Production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to Adverse Reactions. International Journal of Molecular Sciences. 2024;25(7):3595. doi:10.3390/ijms25073595
BibTeX
@article{Bakos2024,
author = {Bakos, Tamás and Mészáros, Tamás and Kozma, Gergely Tibor and Berényi, Petra and Facskó, Réka and Farkas, Henriette and Dézsi, László and Heirman, Carlo and de Koker, Stefaan and Schiffelers, Raymond and Glatter, Kathryn Anne and Radovits, Tamás and Szénási, Gábor and Szebeni, János},
title = {mRNA-LNP COVID-19 Vaccine Lipids Induce Complement Activation and Production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to Adverse Reactions},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {7},
pages = {3595},
doi = {10.3390/ijms25073595}
}
EUVIMED